Skip to main content

Amgen still sees pandemic impact, with fewer patients starting treatments

Amgen Inc. stock fell in the extended session Tuesday after the pharma company reported rising adjusted profit for the third quarter but said the pandemic-related gap in doctor's office visits and fewer people starting treatments continue to impact its business.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.